Targeting HER 1 and 2 in breast cancer with lapatinib
Numerous clinical trials support the biological relevance of the HER2 oncoprotein in breast cancer. In spite of improved outcomes, overexpression of the receptor is associated with increased risks of disease relapse, even in patients with early, and potentially curable, disease. Until recently, deve...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-12-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | http://oncologyreviews.org/index.php/or/article/view/105 |